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It is widely accepted that atherosclerosis is a chronic inﬂam-
matory vascular disease [1]. The formation and progression of
atherosclerotic plaques has four steps, which is including macro-
phage recruitment, endothelial dysfunction, smooth muscle cell
migration and proliferation, and the development of vascular lipid
lesions [2e7].
Osteopontin (OPN), a bone-speciﬁc sialoprotein, was ﬁrst cloned
from rat sarcoma cells [8,9]. It is expressed in several cells and
areas, including the mineralized bone matrix, macrophages, den-
dritic cells, endothelial cells, smooth muscle cells and epithelial
cells [8,10e12]. OPN has been studied as a multifunctional protein
that is upregulated in wound healing [13], ﬁbrosis [14], autoim-
mune disease [15], and atherosclerosis [16]. It is also highly
expressed at sites with atherosclerotic plaques, especially those
associated with macrophages and foam cells. In the context of
atherosclerosis, OPN is generally regarded as a proinﬂammatory
and proatherogenic molecule.
The rennin-angiotensin-aldosterone system (RAAS) is one of the
most important hormonal systems. Over the past decades, several
studies revealed that ACE2, angiotensin-(1e12), angiotensin-(1e9)
and angiotensin-(1e7) take part in the RAAS axis [17e22].* Corresponding author.
E-mail address: diao.hy@163.com (H. Diao).
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effects of Ang II on the kidney include recruitment of inﬂammatory
cells to the glomerulus [23], induction of collagen type IV synthesis
in the glomerular basement membrane, enhancement of an in-
ﬂammatory response in the proximal tubular cells [24], and the
renal tubular interstitium and on cardiac remodeling [25,26]
involve hypertrophy [27], and ﬁbroblast proliferation [28]. It is a
main player in the pathogenesis of hypertensive nephropathy,
which is a leading cause of chronic kidney disease and its pro-
gression to end stage renal disease [29]. Ang II appears to indirectly
promote these functions through its effects on enhanced produc-
tion of osteopontin, ﬁbronectin, collagen, and other matrix pro-
teins, each of which can bind to different integrins [30e35]. This
context aims to critically assess current understanding of the role of
OPN and Ang II in the atherosclerotic process, and interaction be-
tween each other.
2. Role of OPN in atherosclerosis
Atherosclerosis is a chronic inﬂammatory disease which is
triggered by a proinﬂammatory process including endothelial
dysfunction and high levels of circulating cholesterol. This is fol-
lowed by lipid-laden macrophage (foam cell) accumulation in the
subendothelial space of damaged endothelium within the vascular
wall of medium- and/or small-sized arteries [2e7]. OPN is found at
the site of atherosclerotic lesions, especially in association with
macrophages and foam cells, suggesting that OPN plays an impor-
tant role in the development and progression of atherosclerosis,
vascular remodeling, and restenosis [36,37].
In recent years, some studies have attempted to deﬁne the role
of OPN in atherosclerosis, and examined its effect of overexpression
or deﬁciency in atherosclerotic lesion formation. It was shown that
when both OPN transgenic and wild type mice were exposed to
atherogenic diets, the former exhibited enhanced aortic athero-
sclerotic disease. Chiba et al. [38] examined OPN overexpression on
atherosclerosis in fat-fed mice, ﬁnding that transgenic over-
expression of OPN in lymphoid tissues via an IgG enhancer/SV40
promoter was associated with an increase in aortic lesion size.
Consistently, Isoda et al. [39] showed that wide tissueunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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mononuclear cell-rich lesion formation. Also, Takemoto M [40]
found that, in diabetic vascular disease, high glucose concentra-
tions increased the secretion of OPN from cultured rat aortic
smooth muscle cells. In addition, these ﬁndings correlated with
decreased expression of IL-10, a well-established atheroprotective
cytokine, thus suggesting possible mechanisms of OPN effects on
lesion formation and progression. One of the mechanisms is the
Rho/Rho kinase pathway in vascular smooth muscle cells [41].
Another is via the nuclear factor of activated T-cells (NFAT) [42].
On the other hand, Bishop E et al. [43] demonstrated that in vitro
exposure to cigarette smoke extract induced OPN expression in
human endothelial cells in an oxidative stress-dependent manner.
Furthermore, in humans, serum OPN was decreased following
short-term smoking cessation.
The molecular mechanisms includes that OPN regulates
recruitment of inﬂammatory cells and adhesion or migration of
foam cells by binding to integrins (avb3, avb1, avb5, and a4b1) or
the splice variant of CD44 v3-v6, AT1, or AT2, which are OPN re-
ceptors [44,45].
Collectively, OPN seems to exert an essential role in formation of
the atherosclerotic plaque and in enhancing plaque inﬂammation.
It takes part in the vasculopathy by escalating endothelial and
vascular smooth muscle cells proliferation and remodeling. It also
contributes to accelerate atherosclerosis induced by several clas-
sical risk factors/conditions.
3. Ang II signalling in the cardiovascular system
The RAAS (rennin-angiotensin-aldosterone system) is involved
in the development of various cardiovascular diseases (CVDs) such
as hypertension and end-organ damage, diabetes, atherosclerosis
and cardiac remodeling, including hypertrophy and ﬁbrosis, major
risk factors for heart failure [46,47]. The classical RAAS pathway
involves the release of renin from the kidneys into the circulation in
response to low volume states and high sodium content within the
distal tubules. In the blood, the liver-derived angiotensinogen–
angiotensin (Ang) I, is hydrolyzed by angiotensin-converting
enzyme (ACE) to the active octapeptide Ang II [23]. Ang II has
important roles in blood pressure homeostasis and individual tis-
sues. These effects are mediated by the angiotensin type 1 and type
2 receptors (AT1R and AT2R, respectively) [48]. AT1R and AT2R are
transmembrane G protein-coupled receptors (GPCRs) that tend to
have opposing actions (Fig. 1). AT1R is mainly responsible for theFig. 1. Ang II and Receptors activation and their opposite factions.classical pathophysiological actions of Ang II, whereas Ang II
stimulation of the AT2R is reported to antagonize the pathological
effects of AT1R [49e51].
Many studies indicate that RAAS, especially Ang II might regu-
late all stages of atherogenesis, from initiation through disease
progression, determining plaque vulnerability till ﬁnal rupture
[52,53]. First of all, Ang II promotes inﬂammation via RAAS. Ang II/
AT1 signaling pathway leads to an increase in cytokine and che-
mokine expression, including monocyte chemoattractant protein-1
(MCP-1), IL-6, IL-18, TNF-a and IL-1b [54e57] and so on. Inﬂam-
matory cells then have an endogenous RAAS that can produce Ang
II, which results in a positive feedback response, perpetuating the
inﬂammatory cycle [58e60]. Mazzolai et al. [53] demonstrated that
endogenous Ang II contributes to the modiﬁcation of stable plaques
into a vulnerable lesions for the ﬁrst time. This persistent pro-
inﬂammatory state seems to play an essential role in the conver-
sion of a stable atherosclerotic plaque into a vulnerable phenotype
[61e64].
On the other hand, besides promoting inﬂammation via some
processes, such as the release of IFN-g, which inhibits the prolif-
eration of SMCs and decreasing SMC matrix synthesis [65], some
studies demonstrated an increase in SMC apoptosis within
atherosclerotic plaques [66,67]. Among these Ang II induced SMC
apoptosis via AT2 receptor activation, but not AT1 receptor pathway
[68]. Dimmeler S et al. [69] and Li D et al. [70] demonstrated that
Ang II induces apoptosis through activation of AT1 and AT2 re-
ceptors in endothelial cells. These different responses could be also
a consequence of an imbalance between AT1 and AT2 receptor-
mediated responses. Therefore, it is necessary to further investi-
gate these mechanisms.
4. Macrophages in atherosclerosis
In hematopoiesis, two growth factors such as granulocyte-
macrophage colony-stimulating factor (GM-CSF) and macrophage
colony-stimulating factor (M-CSF) drive monocyte to M1 and M2
subsets of macrophages [71]. The M1 phenotype of activated
macrophages is induced by TNF-a and IFN-g and LPS, ﬂagellin
[72e76]. The anti-inﬂammatory M2 macrophage phenotype is
induced by Th2-type cytokines [77]. The atherosclerotic lesion is
highly inﬂammatory and, like other chronic inﬂammatory diseases,
is characterized by the persistence of macrophages and other im-
mune cells. Macrophages and lipid-ﬁlled macrophages [74e76].
More advanced lesions become complex. Macrophages and foam
cells are persistent even in very advanced lesions. They are espe-
cially localized in the shoulder region of the plaque, suggesting an
unrelenting chronic inﬂammatory response [78].
Macrophages are essential players in induction and progression
of atherosclerotic inﬂammation. Recently, Wolfs IM [79] studied
distribution of M1 and M2 macrophages in human plaques and
showed that both types increase in numbers along with the plaque
progression and are equally distributed in the ﬁbrous cap region.
M1-speciﬁc cell markers were preferentially detected in rupture-
susceptible shoulder regions whereas M2-speciﬁc markers were
predominant in the adventitia. Chinetti-Gbaduidi et al. [80] iden-
tiﬁed M2 macrophages in more stable plaque regions out of the
lipid core. M2-enriched lesion areas expressed high levels of IL-4, a
cytokine that is essential for M2 polarization of macrophages. The
observed macrophage population was relatively more resistant to
formation of foam cells and had increased ability to store engulfed
cholesterol esters compared to M1 and resting macrophages [80].
M1-speciﬁc markers were shown to be increased in carotid
atherosclerotic lesions while M2 markers were preferentially
located in femoral atherosclerotic plaques. In addition, plaque M1
macrophages were shown to have up-regulated expression of
Y. Ding et al. / Biochemical and Biophysical Research Communications 471 (2016) 5e9 7several MMPs. Indeed, these observations suggest that M1 macro-
phages are preferentially accumulated in symptomatic and unsta-
ble plaques. Also, immunohistochemistry analysis demonstrated
that both grossly normal-appearing sites and atherosclerotic le-
sions of the human aorta contained TNF-a, a highly relevantmarker
of M1 macrophages (Fig. 2) [81e83].Fig. 3. Putative signaling cascade for Ang IIeinduced OPN expression.
5. Osteopontin modulates angiotensin IIeinduced
inﬂammation in atherosclerosis
OPN is a secreted protein by a variety of cells, such as osteoclasts,
VSMCs, activated T cells, and activated macrophages. Enhancing
IFN-g and IL-12 production and decreasing IL-10, OPN is considered
as potential pro-inﬂammatory cytokine associated with inﬂam-
matory processes [84,85]. Under normal conditions, OPN is not
expressed in the arterial wall. But, in the conditions of atheroscle-
rosis, hypertension and vascular injury, OPN expression is increased
dramatically. And Ang II profoundly induces OPN expression in the
arterial wall [86]. Ang II-induced atherosclerosis is attenuated in
OPN/ mice, suggesting that OPN is a potential mediator in the
development of Ang II-induced pathologies [87]. Talya Wolak et al.
[88] discovered that Ang II infusion increases OPN expression in
mouse. In vivo analysis indicated that OPN functioned similarly to
Ang II by increasing TGF-b1, a-SMA and ﬁbronectin expression, but
unlike Ang II, OPN reduced PAI-1. Similarly, in vitro studies revealed
that both Ang II and OPN increased TGF-b1 and a-SMA but
decreased PAI-1 expression [25,89,90]. These studies suggest that
OPN may exert both pro- and anti-inﬂammatory effects to modu-
late the deleterious effects of Ang II on inﬂammation, oxidative
stress, and renal ﬁbrosis.
The RAAS plays a key role in regulating the cardiovascularFig. 2. Main macrophage subpopulation found in atherosclerotic lesions. Stimuli
present in atherosclerotic lesions drive the differentiation of monocytes towards
different macrophage phenotypes.system. It is widely accepted that Ang II signalling through ATR1
promotes cardiovascular events. Some studies demonstrated that
bymodulating processes involved in inﬂammation, oxidative stress
and ﬁbrosis, OPN may inﬂuence kidney damage in Ang II induced
hypertension [87]. Activation of the RAAS accelerates development
of atherosclerosis and other cardiovascular diseases [91]. Ang II
functions as a potent proinﬂammatory stimulus and upregulates
the expression of many redox-sensitive cytokines, chemokines, and
growth factors involved in the pathogenesis of atherosclerosis,
including OPN [86,87].
OPN expression is induced by Ang II in different cell types, such
as VSMC, macrophages, and epithelial cells of renal tubules. In the
process of heart failure, kidney disease, and atherosclerosis, the
express of Ang II is also associated with that of OPN [92,93]. The
mechanism that the expression of OPN induced by Ang II is
complicated. Keiko ABE et al. [35] study demonstrates that Ang
IIeinduced OPN expression in VSMC is mediated by Gq/11, Ras, and
ERK, and also involves non-receptor tyrosine kinases, such as Pyk2/
CADTK and the Src kinase family members. AT1, the main Ang II
receptor expressed in VSMC, is coupled to multiple heterotrimeric
GTP-binding proteins, including Gaq/11, Ga12/13 and Gai. Inhibiting
of Gaq/11 completely inhibited Ang IIeinduced OPN expression,
indicating that Gaq/11 plays a crucial role in Ang IIeinduced OPN
(Fig. 3).
In conclusion, OPN is highly expressed in the activated macro-
phages under inﬂammatory conditions and during the formation of
atherosclerotic plaques, OPN is highly expressed in macrophages,
VSMCs, and ECs. On the other hand, the RAAS plays a critical role in
the pathogenesis of many vascular diseases extracellular matrix
defects, atherosclerosis and ageing. In this review, we also
comment the relationship between OPN and Ang II in atheroscle-
rosis. Though, the precise mechanisms by which these components
induce vascular damage still need further study.
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